Brind.

VOR partnered with RemeGen for telitacicept licensing.

6 reports, 3 independent Updated Aug 11
Gone quiet Reached 2 outlets in its first 24 hours
Reports
6
Developments
2
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

VOR partnered with RemeGen for telitacicept licensing.

Who's involved

What this event is mainly about
VOR

How it developed

Newest first. Tap a step to see who reported it.
  1. VOR announced a licensing partnership with RemeGen for telitacicept.1 source
  2. Zuraw's experience at RemeGen supports VOR's focus.1 source

Keep exploring

The entities involved

  • VOR

    company in the Czech Republic

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • BioPharma DiveVor says drug licensed from RemeGen succeeded in Sjögren’s study This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive
  • GlobeNewswireVor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approv
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet